Home
NewsNewsINVO Fertility acquires Family Beginnings in a strategic move to expand its U.S. footprint and strengthen patient-centered reproductive care. The acquisition integrates advanced IVF and INVOcell services, reinforces operational growth, and ensures leadership continuity under Dr. James Donahue within INVO’s expanding clinical network.
Feb. 19, 2026 – INVO Fertility, a leader in expanding access to assisted reproductive technology, announced the successful closing of its acquisition of Family Beginnings, P.C. This finalization marks the completion of the strategic transaction first detailed in the company's previous announcement.
The acquisition of the Indiana-based clinic was executed according to the terms of the definitive purchase agreement, with INVO acquiring the non-clinical assets for a combined purchase price of $760,000, $1 million in revenue, and $0.2 million in net income for the nine months ending September 30, 2025. This performance accounted for nearly 18% of INVO’s total clinic revenue during that period.
INVO Fertility acquires Family Beginnings with a clear focus on maintaining the high standard of personalized, patient-first care for which the clinic is known. To ensure a seamless transition and continuity of care, James Donahue, M.D., the clinic’s REI and lab director, has entered into a multi-year agreement to continue leading operations. Dr. Donahue, recently recognized as a 2026 Castle Connolly Top Doctor, brings decades of expertise to the INVO network.
The clinic offers a comprehensive suite of reproductive services, including traditional IVF, ovulation induction, and intrauterine insemination. Notably, Family Beginnings was an early adopter of INVO’s proprietary INVOcell solution, an intravaginal culture (IVC) procedure that allows fertilization to take place in vivo within the woman’s body.
Steve Shum, CEO of INVO Fertility, highlighted the strategic importance of the deal, stating that it expands the company’s geographic footprint while advancing its mission to provide affordable, high-quality fertility care. The closing follows a period of "meaningful progress" for the company, as INVO continues to execute a growth strategy centered on both organic initiatives and targeted acquisitions.
By integrating Family Beginnings into its growing network of operational U.S. clinics, INVO Fertility aims to leverage its broader clinical resources and ongoing investment in advanced technologies to support patients through the emotional journey of reproductive treatment.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
